Alvaiz™ (eltrombopag) – New drug approval
November 29, 2023 - The FDA approved Teva’s Alvaiz (eltrombopag) tablets, for the treatment of: thrombocytopenia in adult and pediatric patients 6 years and older with persistent or chronic immune thrombocytopenia who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy; thrombocytopenia in adult patients with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy; and adult patients with severe aplastic anemia who have had an insufficient response to immunosuppressive therapy.
Top